🔍 Halo’s Aura™ platform enhances particle analysis, complementing Waters’ Wyatt Technology™ solutions.
🚀 This acquisition allows Waters to innovate in large molecule development and QA/QC, improving safety during manufacturing.
🤝 Both companies share a vision for innovation and customer focus, promising advancements in therapeutic quality and safety.
Introduction:
This article discusses the acquisition of Halo Labs by Waters, a move aimed at enhancing Waters’ capabilities in analytical and bioprocessing testing, particularly for large molecule therapies like cell and gene therapies. The acquisition underscores Waters’ commitment to advancing innovative technologies in the biopharmaceutical sector.
- Waters has acquired Halo Labs, which specializes in imaging technologies for detecting and analyzing interfering materials in therapeutic products.
- Halo Labs’ Aura™ platform offers full spectrum particle analysis, complementing Waters’ existing light scattering detection solutions.
- The acquisition enables the integration of cutting-edge particle analysis technology into Waters’ large molecule development and quality assurance processes.
- According to Waters’ CEO Udit Batra, this technology enhances safety during manufacturing and expedites insights during therapeutic development.
- Rick Gordon, CEO of Halo Labs, expressed that the partnership aligns with shared values of innovation and customer focus, aiming to improve drug quality and development processes.
Conclusion:
The acquisition of Halo Labs by Waters represents a strategic advancement towards enhancing analytical capabilities in the biopharmaceutical arena, specifically for burgeoning therapies such as CAR T-cells. This partnership not only aims to enrich Waters’ technology portfolio but also reflects a commitment to improved therapeutic quality and safety, which is crucial as the market for large molecule therapies continues to expand.
